Evotec OAI signs medicinal chemistry agreement with Axxima Pharmaceuticals
Drug discovery services company Evotec OAI, of Hamburg in Germany and Abingdon in the UK, has signed a medicinal chemistry agreement with drug discovery and development company Axxima Pharmaceuticals, based in Munich, Germany, to design and synthesise small molecule lead structures for one of Axxima's leading kinase targets.
Drug discovery services company Evotec OAI, of Hamburg in Germany and Abingdon in the UK, has signed a medicinal chemistry agreement with drug discovery and development company Axxima Pharmaceuticals, based in Munich, Germany, to design and synthesise small molecule lead structures for one of Axxima's leading kinase targets.
Under the terms of the contract Evotec OAI will apply its integrated medicinal chemistry platform to optimise initial screening hits already identified by Axxima and rapidly progress them towards novel clinical candidates for clinical trials. Financial details of the collaboration were not disclosed.
Axxima Pharmaceuticals is pioneering the revolutionary approach of generating a Signal Transduction Firewall to combat infections, related disorders and diseases, such as inflammation. The most advanced projects include HIV, hepatitis C, tuberculosis and HCMV. By blocking critical signal transduction pathways required by pathogens for their survival, Axxima's compounds address entirely novel mechanisms for fighting resistance formation. Whereas the goal of conventional medications is to target the disease-causing pathogen directly, the new generation of drugs developed by Axxima will prevent the pathogen hijacking the communication system of the cell for their own purposes.